Skip to main content

Advertisement

SpringerLink
Log in

Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined Emapalumab and PD-1 Blockade

  • Correspondence
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Availability of Data and Materials

All relevant raw data will be freely available to any researcher wishing to use them for non-commercial purposes, without breaching participant confidentiality. For publication-related data, please contact the corresponding author.

References

  1. Al-Salama ZT. Emapalumab: first global approval. Drugs. 2019;79(1):99–103.

    Article  CAS  PubMed  Google Scholar 

  2. Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811–22.

    Article  PubMed  Google Scholar 

  3. Liu P, Pan X, Chen C, et al. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults. Blood. 2020;135(11):826–33.

    Article  CAS  PubMed  Google Scholar 

  4. Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.

    Article  PubMed  Google Scholar 

  5. Song Y, Wang J, Wang Y, et al. PD-1 blockade and lenalidomide combination therapy for chronic active Epstein-Barr virus infection. Clin Microbiol Infect. 2023;29:796.e7-796.e13.

    Article  CAS  PubMed  Google Scholar 

  6. Noseda R, Bertoli R, Muller L, Ceschi A. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports. J Immunother Cancer. 2019;7(1):117.

    Article  PubMed  PubMed Central  Google Scholar 

  7. De Benedetti F, Grom AA, Brogan PA, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82(6):857–65.

    Article  PubMed  Google Scholar 

  8. Lounder DT, Bin Q, de Min C, Jordan MB. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 2019;3(1):47–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Summerlin J, Wells DA, Anderson MK, Halford Z. A review of current and emerging therapeutic options for hemophagocytic lymphohistiocytosis. Ann Pharmacother. 2023;57(7):867–79.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China (82020108003), National Natural Science Foundation of China (81730003), National Key R&D Program of China (2019YFC0840604), Key R&D Program of Jiangsu Province (BE2019798), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Suzhou Science and Technology Program Project (SLT201911) and National Center for Translational Research Open Project (2021ZKMB04), and China Postdoctoral Science Foundation (2023M732540).

Author information

Authors and Affiliations

  1. National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China

    Yue Song, Weiyang Li, Depei Wu, Xuefeng He & Jianhong Fu

  2. Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215031, China

    Yue Song, Weiyang Li, Depei Wu, Xuefeng He & Jianhong Fu

Authors
  1. Yue Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weiyang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Depei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xuefeng He
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jianhong Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JHF and XFH designed and supervised this study; DPW coordinated the study; YS conducted the data analysis and wrote the manuscript. WL did research. All authors critically reviewed the report and approved the final version.

Corresponding authors

Correspondence to Xuefeng He or Jianhong Fu.

Ethics declarations

Ethics Approval

Not applicable.

Consent to Participate

We have obtained consent to participate from the participant.

Consent for Publication

We have obtained consent to publish from the participant.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 22 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Song, Y., Li, W., Wu, D. et al. Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined Emapalumab and PD-1 Blockade. J Clin Immunol 44, 70 (2024). https://doi.org/10.1007/s10875-024-01670-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10875-024-01670-4

Search

Navigation